This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 6, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony
® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34
th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from
March 18-21, 2014 in
The study will be presented by the principal investigator,
Jeffrey I. Joseph, D.O., Vice-Chairman and Director of Research, Department of Anesthesiology and Director of the Artificial Pancreas Center at
Thomas Jefferson University in
Philadelphia, PA, during poster presentations on
Tuesday, March 18, 2014 from
6:00-7:00 PM AST. The poster, entitled "Evaluation of Symphony CGM - a Non-Invasive, Transdermal Continuous Glucose Monitoring System for Use in the Critically Ill" (P439), will highlight the positive results from the multi-center clinical trial of Echo's Symphony CGM System in post-surgical patients in hospital intensive care units (ICUs).
"There is great clinical need in the hospital for a continuous glucose monitoring system that is safe, accurate, and easy to use," commented Dr. Joseph. "The prevention of hyperglycemia, hypoglycemia, and glycemic variability in hospitalized patients remains an important clinical goal to decrease morbidity, mortality, length of stay and cost. The Symphony CGM System demonstrated clinically relevant accuracy and excellent safety in a variety of patients and ICU environments. Future studies are needed to determine whether Symphony CGM can be used to direct therapy and improve glucose control in this patient population."
The International Symposium on Intensive Care and Emergency Medicine is organized by the department of Intensive Care Emergency Medicine of Erasme University Hospital, Universite Libre de
Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine (SIZ). The meeting is held every year in March. Started in 1980, this meeting has become established as one of the largest in its field, now attracting more than 6090 participants from countries worldwide. The objectives of this four day symposium are to provide participants with an up to date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses and other health professionals with an interest in critical care or emergency medicine.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device, the Prelude
® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts, including the statement about Dr. Joseph's poster presentation, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended
December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.